Compare RKLB & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKLB | GMAB |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | 3119 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3B | 31.9B |
| IPO Year | 2020 | 2008 |
| Metric | RKLB | GMAB |
|---|---|---|
| Price | $61.94 | $51.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 12 |
| Target Price | ★ $93.10 | $65.10 |
| AVG Volume (30 Days) | ★ 16.4M | 6.2M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $601,799,000.00 | N/A |
| Revenue This Year | $62.85 | $27.36 |
| Revenue Next Year | $36.96 | $21.44 |
| P/E Ratio | ★ N/A | $1.90 |
| Revenue Growth | ★ 37.96 | N/A |
| 52 Week Low | $37.57 | $23.62 |
| 52 Week High | $150.85 | $59.97 |
| Indicator | RKLB | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 58.85 |
| Support Level | $60.71 | $25.91 |
| Resistance Level | $77.02 | $59.97 |
| Average True Range (ATR) | 4.79 | 3.01 |
| MACD | 1.69 | -0.57 |
| Stochastic Oscillator | 72.38 | 45.97 |
Rocket Lab Corp is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, and rest of the world and earns key revenue from the United States.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.